The Vectura Group PLC (VEC) Rating Reiterated by Numis Securities Ltd

The Vectura Group PLC (VEC) Rating Reiterated by Numis Securities Ltd

A number of other research firms have also commented on VEC. JPMorgan Chase & Co. restated an “overweight” rating and issued a GBX 240 ($3.08) price objective on shares of Vectura Group PLC in a research report on Wednesday, March 22nd. Peel Hunt restated a “buy” rating and issued a GBX 200 ($2.57) price objective on shares of Vectura Group PLC in a research report on Wednesday, March 29th. N+1 Singer restated a “buy” rating and issued a GBX 202 ($2.59) price objective on shares of Vectura Group PLC in a research report on Tuesday, March 21st. Investec restated a “buy” rating and issued a GBX 220 ($2.83) price objective on shares of Vectura Group PLC in a research report on Tuesday, March 21st. Finally, Stifel Nicolaus restated a “buy” rating and issued a GBX 225 ($2.89) price objective on shares of Vectura Group PLC in a research report on Tuesday, March 21st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of GBX 215.13 ($2.76).

Vectura Group PLC (LON:VEC)‘s stock had its “buy” rating reaffirmed by Numis Securities Ltd in a research report issued on Friday, May 12th. They currently have a GBX 214 ($2.75) price target on the stock. Numis Securities Ltd’s price objective would indicate a potential upside of 86.09% from the company’s previous close.

Shares of Vectura Group PLC (LON VEC) traded down 0.690849% during trading on Friday, hitting GBX 116.329628. 2,133,445 shares of the stock traded hands. Vectura Group PLC has a 1-year low of GBX 114.50 and a 1-year high of GBX 166.97. The company’s market cap is GBX 788.31 million. The stock has a 50-day moving average of GBX 133.64 and a 200 day moving average of GBX 141.06.

About Vectura Group PLC

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “LSE:VEC”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment